IMPORTANT INDUSTRY UPDATE
Retatrutide availability: what we know
Eli Lilly has recently intensified legal action against several US-based companies involved in the sale and distribution of unapproved retatrutide products.
These developments are currently focused on the United States. At this time, there is no confirmed immediate ban affecting our European research catalogue. However, wider pressure on suppliers, payment providers and logistics partners may affect future availability, payment options or pricing.
Our commitment
NexaPeptide is closely monitoring the situation. If anything changes, we will communicate it clearly and transparently through our website and customer channels.
Please note: All products offered by NexaPeptide are intended exclusively for legitimate laboratory and analytical research. They are not medicines and are not intended for human consumption.
Stay informed. We will update this page when verified information becomes available.